INmune Bio, Inc. (INMB)

Market Cap	67.26M
Revenue (ttm)	50,000
Net Income (ttm)	-40.80M
Shares Out	26.59M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,695,992
Open	2.310
Previous Close	2.360
Day's Range	2.295 - 2.769
52-Week Range	1.890 - 11.640
Beta	1.34
Analysts	Buy
Price Target	9.53 (+276.68%)
Earnings Date	Jul 31, 2025

About INMB

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2019
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: INMB
• Website: https://www.inmunebio.com

Financial Performance

In 2024, INmune Bio's revenue was $14,000, a decrease of -90.97% compared to the previous year's $155,000. Losses were -$42.08 million, 40.2% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for INMB stock is "Buy." The 12-month stock price target is $9.53, which is an increase of 276.68% from the latest price.

Price Target

$9.53

(276.68% upside)

Analyst Consensus: Buy